ABAiliya Batool

Ailiya Batool

*This is an algorithmically generated author record based on publicly available information.

Ailiya Batool has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Copper-histidine therapy: a targeted metabolic intervention for Menkes disease

    by Ailiya Batool, Huzaifa Mahmood, Anmol Awan, Muhammad Zaid Saeed, Afnan Ahmad Qureshi, Muhammad Adnan Qamar

    Menkes disease (MD) is a rare, X-linked recessive disorder of copper metabolism, characterized by progressive neurodegeneration, connective tissue abnormalities, and the distinctive phenotype of pili torti. The disease is caused by pathogenic variants in the ATP7A gene, which encodes a copper-transporting P-type ATPase essential for cellular copper efflux and delivery of copper to secreted cuproenzymes. Severe forms of MD typically present in early infancy and are associated with rapid neurological decline and death within the first 3 years of life. Currently, therapeutic options are limited, and outcomes are highly dependent on the timing of intervention. Copper-histidine represents a biologically rational intervention designed to bypass defective intestinal copper transport and restore systemic copper availability. Experimental and clinical observations suggest that early administration may partially correct copper deficiency, improve biochemical parameters, and, in selected cases, alter neurological outcomes and survival. This letter summarizes the pathophysiological basis of MD, the rationale for copper-histidine therapy, and the existing evidence supporting its potential role as a disease-modifying intervention when initiated early in life.


  • Open Access

    AMT-130 gene therapy: a promising disease-modifying approach for Huntington’s disease

    by Chisanga Mwape, Afnan Ahmad Qureshi, Muhammad Zaid Saeed, Aleeza Fatima, Aiman Jamil, Huzaifa Mahmood, Ailiya Batool, Abdul Moiz Khan

    Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder caused by expanded Cytosine-Adenine-GuanineCAG repeats in the huntingtin (HTT) gene, leading to the production and accumulation of mutant huntingtin protein and subsequent neuronal dysfunction and loss. Current management remains largely symptomatic, with no established disease-modifying therapy. AMT-130 represents a novel and promising approach aimed at directly targeting the underlying molecular pathology of HD. AMT-130 is a one-time gene therapy that utilizes an adeno-associated virus serotype 5 (AAV5) vector to deliver an engineered microRNA (miHTT) into the caudate and putamen via stereotactic intracerebral infusion. This microRNA selectively reduces HTT mRNA levels, resulting in sustained lowering of mutant huntingtin protein. Preclinical studies in both large-animal and rodent models have demonstrated broad vector distribution, long-term expression, significant reduction in huntingtin levels, improved motor performance, decreased neuronal degeneration, and prolonged survival. Early Phase I/II clinical data indicate a favorable safety profile, reductions in neurofilament light chain levels, and stabilization of motor and functional decline, particularly in high-dose cohorts, suggesting a potential slowing of disease progression. While long-term efficacy and broader clinical validation are still required, AMT-130 shows strong potential to shift HD treatment from purely symptomatic care toward meaningful disease modification. Its success may also pave the way for microRNA-based therapies in other neurodegenerative disorders.